lipid-a and romurtide

lipid-a has been researched along with romurtide* in 2 studies

Reviews

1 review(s) available for lipid-a and romurtide

Article	Year
Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity. Vaccine, 1992, Volume: 10, Issue:14 It is well recognized that immunoadjuvants mainly play two roles; non-specific stimulation of host resistance against infections and cancer, and the potentiation of vaccine immunogenicity. This article reviews the recent results of the development of synthetic immunoadjuvants in our laboratory with special reference to muramyldipeptide (MDP), trehalose dimycolate (TDM), lipid A, chitin and their related compounds. The usefulness of MDP derivative MDP-Lys(L18), which has recently gone on the market as a haematopoietic agent for restoration of leukopenia in cancer patients treated with radiotherapy and chemotherapy, is reviewed. The various approaches to application of synthetic immunoadjuvants to the potentiation of vaccine immunogenicity, including adjuvant formulation, are also discussed. Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Amino Acid Sequence; Animals; Chitin; Cord Factors; Drug Carriers; Forecasting; Humans; Immunity, Innate; Infections; Lipid A; Molecular Sequence Data; Vaccines	1992

Article

Year

Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity.

Vaccine, 1992, Volume: 10, Issue:14

It is well recognized that immunoadjuvants mainly play two roles; non-specific stimulation of host resistance against infections and cancer, and the potentiation of vaccine immunogenicity. This article reviews the recent results of the development of synthetic immunoadjuvants in our laboratory with special reference to muramyldipeptide (MDP), trehalose dimycolate (TDM), lipid A, chitin and their related compounds. The usefulness of MDP derivative MDP-Lys(L18), which has recently gone on the market as a haematopoietic agent for restoration of leukopenia in cancer patients treated with radiotherapy and chemotherapy, is reviewed. The various approaches to application of synthetic immunoadjuvants to the potentiation of vaccine immunogenicity, including adjuvant formulation, are also discussed.

Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Amino Acid Sequence; Animals; Chitin; Cord Factors; Drug Carriers; Forecasting; Humans; Immunity, Innate; Infections; Lipid A; Molecular Sequence Data; Vaccines

1992

Other Studies

1 other study(ies) available for lipid-a and romurtide

Article	Year
Regression of line-10 hepatocellular carcinoma by a less toxic cord factor analogue combined with L18-MDP or synthetic lipid A analogues. Vaccine, 1988, Volume: 6, Issue:5 A transplantable hepatocarcinoma of strain 2 guinea pigs was used as an experimental model for immunotherapy of cancer. 6,6'-Dideoxy-6,6'-bis-mycoloylamino-alpha,alpha- trehalose (TDNM) was found to be more effective in producing regression of transplantable line-10 tumours than 6,6'-di-O-mycoloyl-alpha,alpha-trehalose (TDM) when combined with 6-O-stearoyl muramyldipeptide (L18-MDP). TDNM showed potent antitumour activity in combination with synthetic lipid A of Escherichia coli (compound 506), but not with the lipid A analogues (GLA-59 and 60). As with the combination of MDP derivative and lipid A analogue, MDP derivatives conjugated with GLA-60 (GMD compounds) showed no tumour regression activity of line-10 cells in guinea-pigs. Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cord Factors; Guinea Pigs; Lipid A; Liver Neoplasms; Liver Neoplasms, Experimental; Remission Induction	1988

Article

Year

Regression of line-10 hepatocellular carcinoma by a less toxic cord factor analogue combined with L18-MDP or synthetic lipid A analogues.

Vaccine, 1988, Volume: 6, Issue:5

A transplantable hepatocarcinoma of strain 2 guinea pigs was used as an experimental model for immunotherapy of cancer. 6,6'-Dideoxy-6,6'-bis-mycoloylamino-alpha,alpha- trehalose (TDNM) was found to be more effective in producing regression of transplantable line-10 tumours than 6,6'-di-O-mycoloyl-alpha,alpha-trehalose (TDM) when combined with 6-O-stearoyl muramyldipeptide (L18-MDP). TDNM showed potent antitumour activity in combination with synthetic lipid A of Escherichia coli (compound 506), but not with the lipid A analogues (GLA-59 and 60). As with the combination of MDP derivative and lipid A analogue, MDP derivatives conjugated with GLA-60 (GMD compounds) showed no tumour regression activity of line-10 cells in guinea-pigs.

Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cord Factors; Guinea Pigs; Lipid A; Liver Neoplasms; Liver Neoplasms, Experimental; Remission Induction

1988